Diversified Trust Co Purchases 925 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Diversified Trust Co boosted its position in Dynavax Technologies Co. (NASDAQ:DVAXFree Report) by 3.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,548 shares of the biopharmaceutical company’s stock after acquiring an additional 925 shares during the period. Diversified Trust Co’s holdings in Dynavax Technologies were worth $367,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in DVAX. Eventide Asset Management LLC boosted its holdings in Dynavax Technologies by 103.0% in the fourth quarter. Eventide Asset Management LLC now owns 2,893,435 shares of the biopharmaceutical company’s stock worth $40,450,000 after acquiring an additional 1,468,435 shares in the last quarter. Kynam Capital Management LP raised its stake in shares of Dynavax Technologies by 202.9% in the fourth quarter. Kynam Capital Management LP now owns 1,514,383 shares of the biopharmaceutical company’s stock worth $21,171,000 after purchasing an additional 1,014,383 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Dynavax Technologies by 21.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock worth $50,288,000 after purchasing an additional 644,428 shares during the last quarter. UBS Group AG raised its stake in shares of Dynavax Technologies by 427.2% in the fourth quarter. UBS Group AG now owns 647,911 shares of the biopharmaceutical company’s stock worth $9,058,000 after purchasing an additional 525,012 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Dynavax Technologies by 7.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after purchasing an additional 293,337 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.93, for a total value of $43,126.95. Following the completion of the sale, the director now directly owns 36,905 shares of the company’s stock, valued at $440,276.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.98% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $11.02 on Friday. The company has a current ratio of 15.20, a quick ratio of 14.10 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 183.67 and a beta of 1.28. The stock has a 50 day moving average of $11.50 and a 200 day moving average of $12.41. Dynavax Technologies Co. has a 12 month low of $10.48 and a 12 month high of $15.15.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The business had revenue of $50.79 million for the quarter, compared to analysts’ expectations of $51.98 million. As a group, sell-side analysts forecast that Dynavax Technologies Co. will post 0.12 earnings per share for the current year.

Analyst Ratings Changes

DVAX has been the subject of several analyst reports. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, June 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Dynavax Technologies has a consensus rating of “Moderate Buy” and an average target price of $25.33.

Read Our Latest Report on DVAX

Dynavax Technologies Company Profile

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Further Reading

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXFree Report).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.